These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 35604958)

  • 1. Behavioral features in child and adolescent huntingtin gene-mutation carriers.
    Reasoner EE; van der Plas E; Al-Kaylani HM; Langbehn DR; Conrad AL; Schultz JL; Epping EA; Magnotta VA; Nopoulos PC
    Brain Behav; 2022 Jul; 12(7):e2630. PubMed ID: 35604958
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Abnormal brain development in child and adolescent carriers of mutant huntingtin.
    van der Plas E; Langbehn DR; Conrad AL; Koscik TR; Tereshchenko A; Epping EA; Magnotta VA; Nopoulos PC
    Neurology; 2019 Sep; 93(10):e1021-e1030. PubMed ID: 31371571
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cortical Features in Child and Adolescent Carriers of Mutant Huntingtin (mHTT).
    Reasoner EE; van der Plas E; Langbehn DR; Conrad AL; Koscik TR; Epping EA; Magnotta VA; Nopoulos PC
    J Huntingtons Dis; 2022; 11(2):173-178. PubMed ID: 35275555
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Coupling of D2R Short but not D2R Long receptor isoform to the Rho/ROCK signaling pathway renders striatal neurons vulnerable to mutant huntingtin.
    Galan-Rodriguez B; Martin E; Brouillet E; Déglon N; Betuing S; Caboche J
    Eur J Neurosci; 2017 Jan; 45(1):198-206. PubMed ID: 27717053
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Developmental Trajectory of Height, Weight, and BMI in Children and Adolescents at Risk for Huntington's Disease: Effect of mHTT on Growth.
    Tereshchenko A; van der Plas E; Mathews KD; Epping E; Conrad AL; Langbehn DR; Nopoulos P
    J Huntingtons Dis; 2020; 9(3):245-251. PubMed ID: 32894247
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Abnormal development of cerebellar-striatal circuitry in Huntington disease.
    Tereshchenko AV; Schultz JL; Bruss JE; Magnotta VA; Epping EA; Nopoulos PC
    Neurology; 2020 May; 94(18):e1908-e1915. PubMed ID: 32265233
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pramipexole reduces soluble mutant huntingtin and protects striatal neurons through dopamine D3 receptors in a genetic model of Huntington's disease.
    Luis-Ravelo D; Estévez-Silva H; Barroso-Chinea P; Afonso-Oramas D; Salas-Hernández J; Rodríguez-Núñez J; Acevedo-Arozena A; Marcellino D; González-Hernández T
    Exp Neurol; 2018 Jan; 299(Pt A):137-147. PubMed ID: 29056363
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extensive early motor and non-motor behavioral deficits are followed by striatal neuronal loss in knock-in Huntington's disease mice.
    Hickey MA; Kosmalska A; Enayati J; Cohen R; Zeitlin S; Levine MS; Chesselet MF
    Neuroscience; 2008 Nov; 157(1):280-95. PubMed ID: 18805465
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treadmill exercise delays the onset of non-motor behaviors and striatal pathology in the CAG
    Stefanko DP; Shah VD; Yamasaki WK; Petzinger GM; Jakowec MW
    Neurobiol Dis; 2017 Sep; 105():15-32. PubMed ID: 28502806
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Huntington's disease progression. PET and clinical observations.
    Andrews TC; Weeks RA; Turjanski N; Gunn RN; Watkins LH; Sahakian B; Hodges JR; Rosser AE; Wood NW; Brooks DJ
    Brain; 1999 Dec; 122 ( Pt 12)():2353-63. PubMed ID: 10581228
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impairments to executive function in emerging adults with Huntington disease.
    Pfalzer AC; Watson KH; Ciriegio AE; Hale L; Diehl S; McDonell KE; Vnencak-Jones C; Huitz E; Snow A; Roth MC; Guthrie CS; Riordan H; Long JD; Compas BE; Claassen DO
    J Neurol Neurosurg Psychiatry; 2023 Feb; 94(2):130-135. PubMed ID: 36450478
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A CAG repeat threshold for therapeutics targeting somatic instability in Huntington's disease.
    Aldous SG; Smith EJ; Landles C; Osborne GF; Cañibano-Pico M; Nita IM; Phillips J; Zhang Y; Jin B; Hirst MB; Benn CL; Bond BC; Edelmann W; Greene JR; Bates GP
    Brain; 2024 May; 147(5):1784-1798. PubMed ID: 38387080
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cellular localization of huntingtin in striatal and cortical neurons in rats: lack of correlation with neuronal vulnerability in Huntington's disease.
    Fusco FR; Chen Q; Lamoreaux WJ; Figueredo-Cardenas G; Jiao Y; Coffman JA; Surmeier DJ; Honig MG; Carlock LR; Reiner A
    J Neurosci; 1999 Feb; 19(4):1189-202. PubMed ID: 9952397
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased calbindin-D28k immunoreactivity in striatal projection neurons of R6/2 Huntington's disease transgenic mice.
    Sun Z; Wang HB; Deng YP; Lei WL; Xie JP; Meade CA; Del Mar N; Goldowitz D; Reiner A
    Neurobiol Dis; 2005 Dec; 20(3):907-17. PubMed ID: 15990326
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Huntington disease. A review].
    Bonilla E
    Invest Clin; 2000 Jun; 41(2):117-41. PubMed ID: 10961047
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutant huntingtin's effects on striatal gene expression in mice recapitulate changes observed in human Huntington's disease brain and do not differ with mutant huntingtin length or wild-type huntingtin dosage.
    Kuhn A; Goldstein DR; Hodges A; Strand AD; Sengstag T; Kooperberg C; Becanovic K; Pouladi MA; Sathasivam K; Cha JH; Hannan AJ; Hayden MR; Leavitt BR; Dunnett SB; Ferrante RJ; Albin R; Shelbourne P; Delorenzi M; Augood SJ; Faull RL; Olson JM; Bates GP; Jones L; Luthi-Carter R
    Hum Mol Genet; 2007 Aug; 16(15):1845-61. PubMed ID: 17519223
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Huntingtin immunoreactivity in the rat neostriatum: differential accumulation in projection and interneurons.
    Kosinski CM; Cha JH; Young AB; Persichetti F; MacDonald M; Gusella JF; Penney JB; Standaert DG
    Exp Neurol; 1997 Apr; 144(2):239-47. PubMed ID: 9168825
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Striatal pre-enkephalin overexpression improves Huntington's disease symptoms in the R6/2 mouse model of Huntington's disease.
    Bissonnette S; Vaillancourt M; Hébert SS; Drolet G; Samadi P
    PLoS One; 2013; 8(9):e75099. PubMed ID: 24040390
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HttQ111/+ Huntington's Disease Knock-in Mice Exhibit Brain Region-Specific Morphological Changes and Synaptic Dysfunction.
    Kovalenko M; Milnerwood A; Giordano J; St Claire J; Guide JR; Stromberg M; Gillis T; Sapp E; DiFiglia M; MacDonald ME; Carroll JB; Lee JM; Tappan S; Raymond L; Wheeler VC
    J Huntingtons Dis; 2018; 7(1):17-33. PubMed ID: 29480209
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Striatal molecular alterations in HD gene carriers: a systematic review and meta-analysis of PET studies.
    Niccolini F; Pagano G; Fusar-Poli P; Wood A; Mrzljak L; Sampaio C; Politis M
    J Neurol Neurosurg Psychiatry; 2018 Feb; 89(2):185-196. PubMed ID: 28889093
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.